Patients were excluded if they had any other chronic liver disease other than MASLD/MASH including alcohol, viral, drug-induced, autoimmune, Budd-Chiari syndrome, Wilsons disease, alpha-1-antitrypsin deficiency, hereditary hemochromatosis, primary/secondary biliary cholangitis, primary sclerosing cholangitis, liver disorders in diseases classified elsewhere, and other chronic hepatitis not classified elsewhere
GLP-1: slows stomach emptying, reduces glucagon and increases satiety (fullness)
To perform a patch test, apply a small amount of the product to the inside of your elbow and wait 24 hours
Previous studies of KBP-089 using pair-feeding have demonstrated a weight loss beyond what is obtained through the reduction of appetite, and have clearly indicated that this effect likely entails increased energy expenditure, or at least a maintenance of energy expenditure, despite the reduction of food intake, a parameter known to reduce energy expenditure [12, 17, 29, 43]
